Clinical Trials Browser

Phase 1/2 × Gastro-enteropancreatic neuroendocrine tumor × Carboplatin × Clear all

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Phase 1/2 Enrolling by invitation

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor